Integration of Wearable Sensor Devices Into a Single System to Predict the Onset of Sepsis (IRHIS)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a prospective clinical performance study involving ICU patients at risk of developing sepsis. The study will assess the integration of portable sensor devices into the CPC telemonitoring platform for the collection and visualization of physiological and biomarker data.
The CPC12S device will collect vital physiological parameters, including electrocardiography, oxygen saturation, non-invasive blood pressure, respiratory rate, heart rate, body position, and physical activity. A CPC temperature and humidity sensor will be used for continuous monitoring of body temperature and humidity. In addition, the IDRO investigational sweat lactate sensor will be integrated into the system to collect sweat lactate data.
The study will be conducted in phases. In the first phase, patients will be monitored using the CPC12S device together with the temperature and humidity sensor. In the second phase, patients will be monitored using the CPC system, the temperature and humidity sensor, and the IDRO sweat lactate sensor.
All patients will be monitored for up to 48 hours. The collected data will be analyzed together with clinical information recorded by healthcare professionals. The primary objective is to support prediction of sepsis onset by integrating data from the CPC12S device, the CPC temperature/humidity sensor, and the IDRO sweat lactate sensor. Secondary objectives include completing the integration of the IDRO sensor into the CPC system, validating the IDRO sweat lactate measurements against standard clinical blood lactate measurements, and developing an algorithm based on device-recorded and clinical data for sepsis prediction.
The data collected in this study will not be used to guide clinical decisions during the study. Medical care and clinical decisions will remain under the responsibility of the hospital medical team according to standard clinical practice.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Adult patients aged 18 years or older.
- Patients admitted to the intensive care unit who are at risk of developing sepsis.
- Patients with one or more relevant risk factors for sepsis, including pre-existing medical conditions, invasive medical devices, recent procedures or conditions, active infections, clinical risk factors, or prolonged ICU/hospital stay.
- Signed informed consent.Exclusion Criteria:
- Inability or unwillingness to provide informed consent or comply with study requirements.
- ICU stay shorter than 6 hours.
- Damaged tattoos, bare skin, recent scar tissue, inflammation, infection, skin barrier alteration, serous or bloody discharge, or metal plates/nails at the area where the Macroduct Advanced system and IDRO device will be placed.
- Patients admitted to the ICU with already diagnosed sepsis.
- Patients participating in other clinical studies.
- Moribund patients or patients with very short life expectancy.
- Patients with do-not-resuscitate status at admission.
- Patients with implanted devices such as an implanted defibrillator, implanted neurostimulator, implanted pacemaker, or implanted ECG monitor.
- Patients in whom short-term interference between the Macroduct device and clinical monitoring cannot be accepted.
- Patients with a history of epilepsy or seizures.
- Pregnant patients or patients who may be pregnant.
- Patients with previous adverse reactions to electrotherapy.
- Patients who present adverse reactions during the first sampling with the Macroduct device.
- Patients for whom the procedure is contraindicated for medical reasons according to the physician's decision.
- Patients with known sensitivity or allergy to pilocarpine nitrate, or any medical contraindication to pilocarpine administration.
- Patients in environments with flammable anesthetics or oxygen-enriched environments.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: CPC12S + Temperature/Humidity Sensor
Participants will be monitored using the CPC12S telemonitoring device together with the CPC temperature and humidity sensor.
Data will include physiological parameters, body temperature, and humidity during ICU monitoring.
|
The CPC12S telemonitoring system will be used together with the CPC temperature and humidity sensor to collect physiological parameters, body temperature, and humidity data from ICU patients during the monitoring period.
|
|
Experimental: CPC12S + Temp/Humidity + IDRO Sensor
Participants will be monitored using the CPC12S telemonitoring system together with the CPC temperature and humidity sensor and the investigational IDRO sweat lactate sensor.
Data will include physiological parameters, temperature, humidity, and sweat lactate measurements.
|
The CPC12S telemonitoring system will be used together with the CPC temperature and humidity sensor to collect physiological parameters, body temperature, and humidity data from ICU patients during the monitoring period.
The investigational IDRO sweat lactate sensor will be used to collect sweat lactate measurements.
The sensor will be integrated with the CPC system for data transmission, visualization, and analysis.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Area under the receiver operating characteristic curve (AUC-ROC) of the integrated sensor-based model for prediction of sepsis onset
Periodo de tiempo: Up to 48 hours of patient monitoring
|
The primary outcome is the predictive performance of the integrated sensor-based model for identifying sepsis onset in ICU patients.
The model will use data collected from the CPC12S telemonitoring system, the CPC temperature/humidity sensor and, where applicable, the IDRO sweat lactate sensor.
Sepsis onset will be determined by the clinical diagnosis recorded by the treating medical team and assessed according to Sepsis-3 criteria.
Predictive performance will be reported as the area under the receiver operating characteristic curve (AUC-ROC).
|
Up to 48 hours of patient monitoring
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Correlation between IDRO sweat lactate measurements and standard blood lactate measurements
Periodo de tiempo: Up to 48 hours of patient monitoring
|
The correlation between sweat lactate values measured by the IDRO sensor and blood lactate values measured as part of routine ICU clinical practice will be assessed using Pearson or Spearman correlation coefficients.
|
Up to 48 hours of patient monitoring
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 101160941
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .